Bora Pharmaceuticals Co., LTD. (TPE:6472)
692.00
-6.00 (-0.86%)
Apr 2, 2025, 1:30 PM CST
TPE:6472 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 3,939 | 3,030 | 1,392 | 749.74 | 578.43 | Upgrade
|
Depreciation & Amortization | 968.8 | 563.53 | 285.23 | 185.31 | 139.8 | Upgrade
|
Other Amortization | 57.53 | 42.76 | 39.95 | 24.85 | 1.23 | Upgrade
|
Loss (Gain) From Sale of Assets | 27.99 | 5 | 3.38 | 2.22 | 0 | Upgrade
|
Loss (Gain) From Sale of Investments | -11.56 | 1,044 | 47.79 | -0.78 | 0.9 | Upgrade
|
Loss (Gain) on Equity Investments | 0.04 | - | - | - | - | Upgrade
|
Stock-Based Compensation | 135.98 | 102.81 | 31.83 | 15.77 | 28.71 | Upgrade
|
Other Operating Activities | -1,274 | 317.17 | 205.67 | 309.69 | -372.97 | Upgrade
|
Change in Accounts Receivable | -1,372 | 2,157 | -1,509 | -282.39 | -217.99 | Upgrade
|
Change in Inventory | -341.82 | -124.5 | 99.39 | 172.37 | -190.93 | Upgrade
|
Change in Accounts Payable | -663.52 | -90.88 | 107.17 | 9.81 | 162.89 | Upgrade
|
Change in Unearned Revenue | 19.31 | 134.72 | -11.77 | 16.36 | -1.55 | Upgrade
|
Change in Other Net Operating Assets | -505.36 | -2,569 | 1,318 | 33.68 | 49.26 | Upgrade
|
Operating Cash Flow | 980.81 | 4,614 | 2,010 | 1,237 | 177.79 | Upgrade
|
Operating Cash Flow Growth | -78.74% | 129.53% | 62.54% | 595.56% | -23.29% | Upgrade
|
Capital Expenditures | -528.1 | -297.71 | -194.81 | -163.48 | -149.23 | Upgrade
|
Sale of Property, Plant & Equipment | 12.59 | 3.37 | 37.95 | 0.08 | 0.14 | Upgrade
|
Cash Acquisitions | -10,265 | -999.99 | -4,514 | -3.83 | -1,383 | Upgrade
|
Divestitures | - | - | 24 | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -158.95 | -1,132 | -5.41 | -200.1 | -2.86 | Upgrade
|
Investment in Securities | 422.21 | -41.7 | 323.98 | - | 67.35 | Upgrade
|
Other Investing Activities | -163.23 | 10.92 | 47.49 | 141.48 | -70.56 | Upgrade
|
Investing Cash Flow | -10,680 | -2,458 | -4,281 | -225.85 | -1,538 | Upgrade
|
Short-Term Debt Issued | 1,824 | - | 772.33 | - | 992.65 | Upgrade
|
Long-Term Debt Issued | 15,021 | 4,804 | 5,554 | 100 | 540.62 | Upgrade
|
Total Debt Issued | 16,844 | 4,804 | 6,327 | 100 | 1,533 | Upgrade
|
Short-Term Debt Repaid | - | -1,398 | - | -572.17 | - | Upgrade
|
Long-Term Debt Repaid | -2,910 | -5,176 | -1,916 | -172.03 | -124.58 | Upgrade
|
Total Debt Repaid | -2,910 | -6,574 | -1,916 | -744.2 | -124.58 | Upgrade
|
Net Debt Issued (Repaid) | 13,934 | -1,769 | 4,411 | -644.2 | 1,409 | Upgrade
|
Issuance of Common Stock | 94.89 | 33.94 | 3.9 | 66.91 | 271.11 | Upgrade
|
Repurchase of Common Stock | -389.13 | - | -53.09 | - | - | Upgrade
|
Common Dividends Paid | -1,233 | -619.13 | -238.8 | -109.77 | -83.25 | Upgrade
|
Other Financing Activities | -336.63 | -85.72 | 471.9 | -54.34 | -18.99 | Upgrade
|
Financing Cash Flow | 12,071 | -2,440 | 4,595 | -741.4 | 1,578 | Upgrade
|
Foreign Exchange Rate Adjustments | 404.86 | 56.13 | 46.89 | -28.63 | 0.03 | Upgrade
|
Net Cash Flow | 2,776 | -228.03 | 2,371 | 240.76 | 217.31 | Upgrade
|
Free Cash Flow | 452.71 | 4,316 | 1,815 | 1,073 | 28.56 | Upgrade
|
Free Cash Flow Growth | -89.51% | 137.76% | 69.15% | 3657.55% | - | Upgrade
|
Free Cash Flow Margin | 2.35% | 30.39% | 17.30% | 21.90% | 1.59% | Upgrade
|
Free Cash Flow Per Share | 4.04 | 41.68 | 18.39 | 11.03 | 0.30 | Upgrade
|
Cash Interest Paid | 382.69 | 156.01 | 105.04 | 54.12 | 18.99 | Upgrade
|
Cash Income Tax Paid | 1,057 | 896.47 | 367.75 | 18.16 | 24.05 | Upgrade
|
Levered Free Cash Flow | -4,970 | 3,148 | 1,037 | 625.48 | -467.98 | Upgrade
|
Unlevered Free Cash Flow | -4,670 | 3,255 | 1,105 | 658.99 | -454.25 | Upgrade
|
Change in Net Working Capital | 7,260 | -694.93 | 252.77 | -142.89 | 613.19 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.